Stereotaxis Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)1.27 Intrinsic Value $2.10median of 2 methodsbased on filings through 30 Jun 2026 Market Price $1.20Price as of 1 Oct 2026 Significantly undervaluedIntrinsic value is 75% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (+75%) Data confidence Sign in to view data confidence Market Cap $120.2M Enterprise Value $115M Shares Outstanding 102.6M diluted Next Earnings Date16 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Stereotaxis is transitioning from a legacy technology provider dependent on third-party catheters to a fully integrated, high-margin surgical robotics ecosystem. The recent FDA approvals of its proprietary MAGiC cardiac ablation catheter and Synchrony digital surgery system structurally shift its commercial opportunity. While near-term revenues are pressured by the wind-down of its relationship with Johnson & Johnson, the company's razor-and-blade model is poised for high-margin recurring revenue growth as manufacturing scales. Furthermore, the acquisition of Robocath expands its addressable market into interventional cardiology and neurointerventions, creating a comprehensive endovascular robotic platform. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$3.50 Mean target$4.13 High · most bullish analyst$5.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $3.5015% Manufacturing bottlenecks for the MAGiC catheter persist, preventing the company from meeting demand. The decline in legacy J&J catheter revenue outpaces the ramp-up of proprietary catheters, leading to prolonged net losses and requiring dilutive capital raises. Base CaseCentral scenario $4.0060% Stereotaxis successfully executes its product transition, surpassing $40 million in revenue for FY 2026 with sequential growth exceeding $10 million per quarter in the second half of the year. The company leverages its cash balance of $14.6 million to fund commercialization and Robocath integration without significant shareholder dilution. Bull CaseUpside scenario $4.1325% Rapid manufacturing scale-up of the MAGiC catheter satisfies high demand in the US and Europe, driving sequential revenue acceleration. The integration of Robocath proceeds smoothly, establishing Stereotaxis as the undisputed leader in endovascular robotics and accelerating system placements. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |